Matthew T. Bush

San Diego
  • 12670 High Bluff Drive
  • San Diego, CA 92130
  • USA
 
 

Matt Bush is the Chair of the San Diego office’s Corporate Department. 

Mr. Bush represents life sciences and technology companies ranging from startups to publicly held corporations. He is a sought after advisor in transactional matters ranging from company formation though maturing growth and exit strategy, which includes day-to-day guidance, venture financings, initial public offerings, mergers and acquisitions, SEC disclosures, corporate governance, and aftermarket capital raising.

Prior to entering law school, Mr. Bush was a manager with Accenture, where he assisted clients with business process reengineering and enterprise software implementation.

A selection of Mr. Bush’s representations include:

  • Airgain, a leading provider of embedded antenna technologies used to enable high performance wireless networking across a broad range of home, enterprise, and industrial devices, in general company representation, its initial public offering, strategic acquisitions, and in corporate governance matters
  • Apricus Biosciences in follow-on offerings, corporate governance, and in its reverse merger with Seelos Therapeutics
  • Ballast Point Brewing & Spirits in its proposed initial public offering and US$1.0 billion sale to Constellation Brands
  • BIND Therapeutics in its initial public offering
  • Cadence Pharmaceuticals in its US$1.4 billion sale to Mallinckrodt plc
  • Conatus Pharmaceuticals in its initial public offering, follow-on offerings, and in corporate governance matters
  • Crinetics Pharmaceuticals in venture financings, its initial public offering and in corporate governance matters
  • Cubic Corporation, a technology-driven, market-leading provider of cost-effective systems and solutions that address the mass transit and global defense markets’ most pressing and demanding requirements, in follow-on public offerings and in corporate governance matters
  • DJO Incorporated in its US$1.6 billion sale to an affiliate of The Blackstone Group and acquisitions of Dr. Comfort and Elastic Therapy for US$300 million
  • eFFECTOR Therapeutics in its venture financings with investors such as U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, and Astellas Venture Management
  • Elevation Pharmaceuticals in its venture financings with investors such as Canaan Partners, TPG Growth, Care Capital and Novo Ventures, and in its sale to Sunovion for proceeds of up to US$430 million
  • Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, in formation structuring, venture financings with investors such as ARCH Venture Partners, Andreessen Horowitz and Cormorant Asset Management, and in corporate governance matters
  • Exagen Diagnostics in its bridge financings, proposed initial public offering, and in corporate governance matters
  • Evoke Pharma in venture financings, in its initial public offering, follow-on offerings, and in corporate governance matters
  • Gossamer Bio in formation structuring, venture financings, its initial public offering, strategic acquisitions, and in corporate governance matters
  • Level Studios, an integrated digital marketing and product development agency, in its sale to Rosetta
  • Ligand Pharmaceuticals in strategic acquisitions, public company and corporate governance matters, and convert offering
  • Meritage Pharma in venture financings with investors such as Domain Associates, Latterell Venture Partners and The Vertical Group, and in its sale to ViroPharma Incorporated (with Shire plc as successor in interest) for up to US$240 million
  • Santarus in corporate governance matters, in its secondary public offering, and in its US$2.6 billion sale to Salix Pharmaceuticals
  • Tealium, an innovative technology company that is a leader in real-time customer data management solutions, in venture financings and general company representation
  • Zogenix in its venture financings, initial public offering and follow-on offerings, and in corporate governance matters
  • A number of investment banks in public offerings of equity securities for life sciences companies, including initial public offerings for AltheaDx, Ambit Biosciences, Cirius Therapeutics, Equillium, HTG Molecular, Horizon Pharma, Insys Therapeutics, Lumena Pharmaceuticals (prior to its sale), Poseida Therapeutics, Sophiris Bio, Synthorx, Tocagen, Tracon Pharma, and Trius Therapeutics, as well as public offerings for Ardea Biosciences, Arena Pharmaceuticals, Biocryst Pharmaceuticals, GenMark, Heron, Iovance, GlycoMimetics, Mirati Therapeutics, Neurocrine Biosciences, Optimer Pharmaceuticals, and Vical
Representative Speaking Engagements
  • Speaker, “Getting to the Field - IPO Execution,” Marsh & McLennan IPO Bootcamp
  • Speaker, “Your Company’s Next Step,” KPMG IPO Bootcamp
  • Speaker, “Business Structure and Tax Strategies for Start-ups,” Association of Bioscience Financial Officers (ABFO) National Conference
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.